Sulaiman Al Habib Group posts SAR 870 mln net profit in FY19
Dr. Sulaiman Al Habib Medical Group (HMG) posted a net profit after Zakat and tax of SAR 870.2 million, a rise of 8.6% year-on-year (YoY).
Financials (M)
Item | 2018 | 2019 | Change |
---|---|---|---|
Revenues | 4,587.63 | 5,016.28 | 9.3 % |
Gross Income | 1,362.01 | 1,523.54 | 11.9 % |
Operating Income | 801.52 | 867.72 | 8.3 % |
Net Income | 801.31 | 870.23 | 8.6 % |
Average Shares | 350.00 | 350.00 | - |
EPS (Riyals) | 2.29 | 2.49 | 8.6 % |
The higher profit was driven by a 9.67% increase in full-year revenue to SAR 5 billion, amid better growth in the hospitals and pharmacies segments. Patient footfall also rose by 7.17% across the group’s hospitals.
In addition, the annual figures were also buoyed by higher pharmaceuticals sales and new awards in the solutions segment.
Current Quarter Comparison (M)
Item | Q4 2018 | Q4 2019 | Change |
---|---|---|---|
Revenues | 1,204.57 | 1,404.45 | 16.6 % |
Gross Income | 355.74 | 435.67 | 22.5 % |
Operating Income | 211.62 | 263.49 | 24.5 % |
Net Income | 225.34 | 270.18 | 19.9 % |
Average Shares | 350.00 | 350.00 | - |
EPS (Riyals) | 0.64 | 0.77 | 19.9 % |
View other reports
Share Price
Dr. Sulaiman Al Habib Medical Services Group (SULAIMAN ALHABIB)
Current | |
Market Cap (M Riyal) | 93,800.00 |
Enterprise Value (EV) (M) | 98,768.80 |
Shares Outstanding ((M)) | 350.00 |
EPS ( Riyal) (TTM) | 6.36 |
Book Value (BV) ( Riyal) | 19.97 |
Par Value ( Riyal) | 10.00 |
Adjusted P/E (Last12) | 43.25 |
P/E (TTM) | 42.13 |
Price/book | 13.42 |
Return on Average Assets (%) (TTM) | 13.0 |
Return on Average Equity (%) (TTM) | 33.3 |
Financial results (Million)
Period | Revenues | Change | Gross Income | Change | Operating Income | Change |
---|---|---|---|---|---|---|
Q1 2019 | 1,227.90 | 5.0 % | 404.20 | 11.8 % | 248.18 | 12.3 % |
Q2 2019 | 1,157.19 | 8.3 % | 334.70 | 15.2 % | 163.58 | 6.4 % |
Q3 2019 | 1,226.74 | 7.1 % | 348.97 | (1.5 %) | 192.48 | (10.5 %) |
Q4 2019 | 1,404.45 | 16.6 % | 435.67 | 22.5 % | 263.49 | 24.5 % |
2019 | 5,016.28 | 9.3 % | 1,523.54 | 11.9 % | 867.72 | 8.3 % |
Profit Performance (Million)
Period | Net Income | Change | EPS(Riyal) | Extraordinary Income/Expense | Net Profit Before Unusual Items | EPS Before XO Items |
---|---|---|---|---|---|---|
Q1 2019 | 234.08 | 8.1 % | 0.67 | - | 234.08 | 0.67 |
Q2 2019 | 167.97 | 10.9 % | 0.48 | - | 167.97 | 0.48 |
Q3 2019 | 198.00 | (4.8 %) | 0.57 | - | 198.00 | 0.57 |
Q4 2019 | 270.18 | 19.9 % | 0.77 | - | 270.18 | 0.77 |
2019 | 870.23 | 8.6 % | 2.49 | - | 870.23 | 2.49 |
Profitability
Period | Gross Margin | OIBDA Margin | Net Margin Before Unusual Items |
---|---|---|---|
Q1 2019 | 30.24 % | 22.28 % | 17.62 % |
Q2 2019 | 30.60 % | 22.42 % | 17.64 % |
Q3 2019 | 29.97 % | 21.82 % | 17.14 % |
Q4 2019 | 30.37 % | 22.40 % | 17.35 % |
2019 | 30.37 % | 22.40 % | 17.35 % |
Compared With The
Per Share Data (Riyal)
Period | Shares Outstanding (M) | EPS (Riyal) | Adjusted EPS (Riyal) | Book Value (BV) |
---|---|---|---|---|
Q1 2019 | 350.00 | 2.34 | 2.34 | 12.43 |
Q2 2019 | 350.00 | 2.39 | 2.39 | 11.79 |
Q3 2019 | 350.00 | 2.36 | 2.36 | 12.36 |
Q4 2019 | 350.00 | 2.49 | 2.49 | 12.55 |
Multiple Ratios (End of Period Price)
Period | P/E | Adjusted P/E | Price/book |
---|---|---|---|
Q1 2019 | - | - | - |
Q2 2019 | - | - | - |
Q3 2019 | - | - | - |
Q4 2019 | - | - | - |
Business Segments (Million)
Q4 2019
Period | Hospitals | Pharmacies | Others |
---|---|---|---|
Q1 2019 | 999.00 | 208.00 | 21.00 |
Q2 2019 | 916.00 | 201.00 | 40.00 |
Q3 2019 | 984.00 | 203.00 | 40.00 |
Q4 2019 | 1,102.00 | 242.00 | 60.00 |
Analysts Estimates (Million)
Item | Q4 2019 (e) | Q4 2019 (a) | Change |
---|---|---|---|
Average | 270.20 | 270.18 | 0.0 % |
Estimates vs Actual (Million)
Item | Q4 2019 (e) | Q4 2019 (a) | Change |
---|---|---|---|
OSOOL AND BAKHEET | 270.20 | 270.18 | 0.0 % |
Call Request
Comments {{getCommentCount()}}
Be the first to comment
رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}
{{comment.DisplayName}}
{{comment.ElapsedTime}}